Onkologie. 2017:11(5):264-268 | DOI: 10.36290/xon.2017.049
The use of bevacizumab (Avastin) in treating recurrent cervical cancer
- Gynekologicko-porodnická klinika 1. LF UK a Nemocnice Na Bulovce, Praha
Recurrent, persistent or metastatic cervical cancer represents a major clinical problem. It is a tumour with a very unfavourableprognosis, being frequently diagnosed in younger women. The treatment options in the case of such a tumour are limited, mainlyinvolving the administration of systemic palliative chemotherapy with a platinum derivative and/or non-platinum combinations inpretreated patients. More recently, it has been possible to utilize the beneficial effect of anti-angiogenic therapy in the palliativetreatment of this disease. The present case report discusses clinical experience with the treatment of recurrent cervical cancer ina young patient by means of chemotherapy and anti-angiogenic therapy.
Keywords: cervical cancer, recurrence, bevacizumab, anti-angiogenic therapy
Published: November 1, 2017 Show citation
References
- Tewari KS, Monk BJ. Invasive cervical cancer. In: DiSaia PJ, Creasman WT, eds. Clinical gynecologic oncology. 8th ed. Philadelphia: Mosby, 2012.
Go to original source... - Dušek L, Mužík J, Kubásek M, Koptíková J, Žaloudík J, Vyzula R. Epidemiologie zhoubných nádorů v České republice [online]. Masarykova univerzita, 2005, [cit. 29. 10. 2017.] Dostupný z www: http://www.svod.cz. Verze 7.0 [2007], ISSN 1802-8861.
- Leung DW, Cachianes G, Kuang WJ, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246: 1306-9. Go to original source...
Go to PubMed... - Monk BJ, Sill MW, Burger RA, et al. Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 2009; 27: 1069-1074. Go to original source... Go to PubMed...
- Ferrara N, Hillan KJ, Gerber HP, et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004; 3: 391-400. Go to original source... Go to PubMed...
- Tewari KS, Sill MW, Long HJ, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 2014; 370: 734-743. Go to original source... Go to PubMed...
- Pfaendler KS, Tewari KS, et al. Changing paradigms in the systemic treatment of advanced cervical cancer. Am J Obstet Gynecol 2012; 214(1): 22-30. Go to original source... Go to PubMed...
- Martin JY, Urban RR, Liao JB, et al. Bevacizumab toxicity in heavily pretreated recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancers. J Gynecol Oncol. 2016; 27(5): e47. Go to original source... Go to PubMed...
- Nogué-Pujadas E, Lezcano-Rubio C, López-Sisamón D, et al. Gastrointestinal perforation induced by bevacizumab treatment in cervix carcinoma. Farm Hosp. 2015; 39(6): 405-406. Go to PubMed...